Get a deeper look into our methodologies and techniques. Learn about the research that is being conducted in the PEDI-Pharm lab
Pharmacovigilance
Drug-induced liver injury (DILI) is an adverse drug reaction caused by various medications, herbs, or other xenobiotics that can range from mild liver enzyme elevations to severe liver failure and death. Neonatal DILI is poorly studied, with data suggesting certain drugs (e.g., meropenem, fat emulsions, sodium glycerophosphate) and drug combinations may increase risk.
Total Parenteral Nutrition (TPN) is commonly administered to babies in the NICU, PICU or cardiac ICU, as they cannot ingest breast milk enterally. Although some forms of TPN, such as SMOF lipid, have been found to be hepatoprotective, other studies suggest they may contribute to DILI. This study aims to investigate the incidence of DILI among infants exposed to hepatotoxic drugs and evaluate whether long-term TPN administration increases the risk of DILI when used concurrently with commonly prescribed medications. This retrospective cohort study examines infants with varying levels of exposure to TPN and common medications, including meropenem, acetaminophen, ampicillin, morphine, and fluconazole, to assess their hepatotoxicity and potential progression to DILI.
Status: Published
This study explored whether the risk of pulmonary hypertension in preterm infants with retinopathy of prematurity (ROP) increases following treatment with anti-vascular endothelial growth factor (VEGF) therapy, compared with laser treatment. Findings from this retrospective cohort study of 1577 patients showed that after adjusting for site and year of treatment, anti-VEGF therapy for ROP was associated with a 2.4% statistically not significant increase in the risk of medical therapy for pulmonary hypertension. These findings support investigating pulmonary hypertension as a potential adverse effect within studies of anti-VEGF therapies in preterm infants.
Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity
Pharmacovigilance
Status: Ongoing study
Opiates are an important tool to manage post-operative pain in children, but there are association and society-level risks of opiate prescriptions. This study aims to quantify total opiate prescriptions in children who received care at The Hospital for Sick Children over many years, to identify trends and understand which pediatric groups receive more opiates than others.
Developmental Pharmacology
Status: Ongoing study
Bronchopulmonary dysplasia (BPD) remains a major complication in preterm infants, and the role of systemic corticosteroids such as dexamethasone in its management remains controversial. Limited knowledge exists regarding the optimal drug concentration needed to achieve therapeutic benefit while minimizing toxicity, as well as the factors contributing to inter-individual variability in drug response. Evidence from a paediatric asthma study suggests that genetic variation in steroid response or steroid modification pathway genes can influence clinical outcomes, but their role in BPD is poorly defined. This analysis uses data from a study on 106 preterm infants treated with dexamethasone to explore whether steroid exposure and response can be predicted using baseline endogenous steroid levels and single nucleotide polymorphisms (SNPs) in steroid disposition and response genes.
Status: Ongoing Study
Clinical pharmacology research aimed at understanding how drugs work, determining the dose required to achieve optimal clinical effect without side effects, requires frequent blood or urine sample collection. This is challenging when the research involves neonates and infants due to safety and ethical restraints on blood drawing as a result of needle pain and limited blood volumes. This study focuses on the collection or “scavenging” of leftover samples (blood, urine) collected as a result of routine clinical care, that would otherwise be discarded once the clinical labs are complete.
Pharmacogenetics and Personalized Medicine
Status: Published
Enoxaparin is a first-line blood thinner used in the Neonatal Intensive Care Unit (NICU). Standard weight-based dosing for enoxaparin often requires repeated dose adjustments and monitoring to reach effective blood levels quickly. Thus, this study examined whether a pharmacokinetic (PK) model-informed precision dosing (MIPD) approach based on an individual infant’s predicted drug clearance and distribution, could improve outcomes. A retrospective analysis of 44 neonates treated with enoxaparin showed that the MIPD approach frequently recommended higher initial doses of enoxaparin when compared with standard dosing. These findings are being used to define dosing limits in a study that applies the MIPD approach in neonatal intensive care settings.
Learn more about the study
Status: Ongoing study
Dexmedetomidine (DEXMED) is a potent alpha-2 agonist that acts on the central nervous system, causing sedation without significant respiratory depression. It is increasingly being used either as a sole agent or as an adjunct to opiates during ICU care of newborns, infants, and children, and was recently suggested as a first-line sedative in all children requiring mechanical ventilation.
Primarily administered as a continuous infusion, dosing practices for DEXMED vary widely across institutions, reflecting an inadequate understanding of the patient-specific characteristics that lead to variability in clinical response. Preterm and term infants, up to 12 months of age, undergo rapid changes in their capacity to metabolize drugs and the expression of drug targets in the brain. In addition, each infant has a unique DNA signature for key genes in drug metabolism and response. The current population-based dosing of DEXMED in infants does not account for either of these variables because they have not been adequately explored. The goal of this study is to investigate the variability in the efficacy and safety of DEXMED in critically ill infants. Specifically, the study aims to understand how genetic, developmental, and illness factors contribute to the varied response to DEXMED in this population.
Status: Ongoing study
Pharmacogenomics (PGx) has become a useful clinical tool to better understand and determine drug tolerability, efficacy, and toxicity. Within the adult population, clear benefit and dosing recommendations have been implemented by national guidelines, and more than 140 drugs now carry warnings about pharmacogenetic variants associated with adverse drug reactions and treatment failures. However, many of these medications with PGx guidance are not commonly used in neonates and infants. There is limited evidence on whether a patient’s pharmacogenomic profile influences clinically significant outcomes for commonly used medications in newborns and infants. Therefore, this retrospective cohort study uses data from the Heart Centre Biobank to examine how pharmacogenetic variation affects the efficacy and toxicity of commonly used drugs in neonates and infants with cardiovascular disease.
Status: Ongoing study
Despite many well-validated pharmacokinetic (PK) models to guide drug dosing in neonates, clinically we still use standard weight based dosing alone (mg/kg) for almost all drugs. By incorporating multiple patient characteristics (age, weight, creatinine, hematocrit) into a model-informed precision dosing (MIPD) tool we can individualize the dosing regimen to give more precise doses with the goal of increasing drug efficacy and decreasing drug toxicity.
Status: Ongoing study
This is a secondary data use study of infants with congenital heart disease and cardiomyopathy. Infants were identified through the Heart Center Biobank (PI Seema Mital) and key pharmacogenetic variants will be identified from existing whole genome sequencing data. Clinical variables will be extracted to assess variability in drug response. Some current drugs of interest that we are exploring include spironolactone, morphine, dexmedetomidine, and furosemide.
Status: Ongoing study
There have been very few studies conducted looking at utilizing pharmacogenomics to aid in antihypertensive dose and agent selection, with most of the current published literature focusing on adult populations. These studies, which highlight known genetic variants in adults, serve as a useful starting point to correlate these findings to younger populations to determine if similar conclusions can be drawn. The overall goal of this study is to establish potential gene-drug associations with efficacy or toxicity of hydralazine (a drug commonly prescribed to treat hypertension) through pharmacogenetic variants within the pediatric population.
Status: Ongoing study
RareKids-CAN is a national network dedicated to advancing pediatric rare disease clinical trial research through collaboration among researchers, clinicians, patients, families, and industry partners across Canada. Our lab leads the Pharmacology Sub-Platform, which develops educational resources and practical tools to support the safe and effective implementation of advanced therapeutic medicinal products (ATMPs) in clinical research and care. Current projects include family-engaged research to identify medication-related educational needs and priorities that will inform future patient and family resources. We also develop educational white papers on cell and gene therapies, conduct environmental scans and landscape analyses of ATMP implementation across Canadian institutions, and create standard operating procedures and workflow resources to support pharmacy and research teams involved in investigator-initiated ATMP clinical trials and care.
